SCHEMBL17570175

SCHEMBL17570175

O=S(=O)(Nc1cc(Oc2ccccc2)cc2cccnc12)c1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC40A1 Q9NP59 12/20 0.78
CKS1B P61024 3/20 0.71
SKP2 Q13309 3/20 0.71
TDP1 Q9NUW8 6/20 0.67
MEN1 O00255 5/20 0.67
KMT2A Q03164 5/20 0.67
AGTR1 P30556 2/20 0.64
POLB P06746 1/20 0.64
LMNA P02545 1/20 0.64
TP53 P04637 1/20 0.64
MAPT P10636 1/20 0.64
HPGD P15428 1/20 0.64
TSHR P16473 1/20 0.64
CXCR2 P25025 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
GLO1 Q04760 2/20 0.64
G6PD P11413 1/20 0.64
NFKBIA P25963 1/20 0.64
METAP2 P50579 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7197593 0.88 SLC40A1 (1.00) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL17570176 0.86 SLC40A1 (0.61) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL11973772 0.85 SLC40A1 (1.00) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL11973341 0.84 SLC40A1 (1.00) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL17506531 0.83 CKS1B (1.00) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL17538432 0.83 CKS1B (0.84) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL11972974 0.82 SLC40A1 (1.00) SLC40A1CKS1BSKP2TDP1AGTR1
SCHEMBL17506534 0.81 CKS1B (1.00) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL11973488 0.81 SLC40A1 (1.00) SLC40A1CKS1BSKP2TDP1MEN1
SCHEMBL11973412 0.81 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10040766-B2 Ubiquitination inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2018-08-07 US disclosed
US-10040766-B2 Ubiquitination inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2018-08-07 US disclosed
US-20160068490-A1 UBIQUITINATION INHIBITORS MIDCAP FINANCIAL TRUST 2016-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068490-A1 UBIQUITINATION INHIBITORS MDM2, RBX1, NEDD4 SLC40A1 4627/4885CKS1B 206/4885SKP2 51/4885
US-10040766-B2 Ubiquitination inhibitors MDM2, RBX1, NEDD4 SLC40A1 4627/4885CKS1B 206/4885SKP2 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.